Researchers found that Emergent BioSolutions has partnered with Substipharm Biologics to manufacture and distribute a vaccine for Japanese Encephalitis (JE), known as IMOJEV®. This partnership, valued at approximately $34.5 million, will enhance the vaccine’s availability in the U.S. once it receives regulatory approval from the FDA. The manufacturing will take place at Emergent’s Canton, Massachusetts facility, which has recently passed an FDA inspection, ensuring compliance with safety standards.

This development is significant for people who travel to areas where Japanese Encephalitis is common, particularly in parts of Asia and the Western Pacific. The vaccine has been in use internationally since 2012, and its availability in the U.S. could provide essential protection against this mosquito-borne viral disease. By increasing access to the vaccine, travelers can better safeguard their health and reduce their risk of contracting JE.

The agreement represents a strategic move to bolster the production of critical vaccines domestically. While the vaccine has been successfully used in other countries, its approval and distribution in the U.S. are still pending regulatory processes. This partnership is a promising step, but it is important to note that the vaccine is not yet available in the U.S. market. The ongoing collaboration aims to streamline the manufacturing process and prepare for future health challenges.

As the vaccine progresses through regulatory channels, travelers should stay informed about vaccination recommendations, especially if they plan to visit JE-endemic regions. Consulting with healthcare providers about vaccination options is advisable to ensure adequate protection.

Source: globenewswire.com